We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Avidity Biosciences Inc | NASDAQ:RNA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.68 | 2.66% | 26.26 | 26.24 | 26.31 | 27.34 | 26.075 | 26.68 | 334,758 | 18:25:16 |
From May 2023 to May 2024
By Dean Seal
Avidity Biosciences has gotten orphan drug designation from regulators for its investigational therapy for the treatment of Duchenne muscular dystrophy.
The biopharmaceutical company said the U.S. Food and Drug Administration granted the designation to AOC 1044, which is being developed to treat Duchenne muscular dystrophy in people with mutations amenable to exon 44 skipping.
Orphan-drug designation is a special status given to drugs that show promise for potentially treating rare, or orphan, diseases that have fewer than 200,000 cases a year in the U.S.
Shares ticked up 1.8% to $8.93 in premarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
August 15, 2023 09:26 ET (13:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Avidity Biosciences Chart |
1 Month Avidity Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
